Investor Relations

Overview

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.

read more

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

AnaptysBio to Present at The 2020 Wedbush PacGrow Healthcare Conference

SAN DIEGO , Aug. 05, 2020 (GLOBE NEWSWIRE) -- AnaptysBio , Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will

AnaptysBio Appoints Dr. Paul F. Lizzul As Chief Medical Officer

Dermatology Physician-Scientist To Lead Wholly-Owned Pipeline Advancement SAN DIEGO , July 31, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms

AnaptysBio Expands Executive Leadership Team

Appoints Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer SAN DIEGO , July 15, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune